Last updated 2 days ago
A Clinical Trial of MK-7262 and Enlicitide in Participants With High Lipoprotein(a) (MK-7262-004)
750 patients around the world
Available in Colombia, United States
Merck Sharp & Dohme LLC
3Research sites
750Patients around the world
This study is for people with
Elevated Lipoprotein A
Requirements for the patient
From 18 Years
All Gender
Medical requirements
- The main inclusion criteria include but are not limited to the following.Has Lp(a) ≥ 150 nmol/L.Is receiving an optimized and stable dose of statin for ≥ 30 days with no planned additions, dose changes, or discontinuations through the duration of the study.
- The main exclusion criteria include but are not limited to the following.Has a history of homozygous familial hypercholesterolemia (FH), compound heterozygous FH, or double heterozygous FH.Has a history of class IV heart failure, severe ventricular systolic dysfunction, uncontrolled ventricular arrhythmia, markedly prolonged corrected QT interval, untreated hypertension, or a recent coronary, cerebrovascular, or peripheral ischemic event or arterial revascularization.Has human immunodeficiency virus infection, unless the infection is controlled (i.e. undetectable viral load).Has an active hepatitis C virus infection or active or chronic hepatitis B virus infection.Has a history of nephrotic syndrome.Has severe renal insufficiency.Has received certain therapies in the prohibited timeframe as specified in the protocol.Has active or chronic hepatobiliary or hepatic disease.Has poorly controlled Type 1 or Type 2 diabetes.
Sites
Salud SURA Industriales
Recruiting
Uniendo Centro de Investigación - Solano y Terront Servicios Médicos Ltda.
Recruiting
Clínica de la Costa - Barranquilla
Recruiting
SponsorMerck Sharp & Dohme LLC
Study typeInterventional
Conditions
Requirements
From 18 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT07614984
